On 2 July 2025 the Enlarged Board of Appeal held that a product put on the market does not fall outside the prior art merely because the skilled person cannot fully analyse or reproduce it.
Background
Under the earlier decision G 1/92, the chemical composition of a product was only part of the prior art if the skilled person could analyse it and reproduce the product. This had given rise to a practice under which non-reproducible marketed products were disregarded.
The decision
The Enlarged Board of Appeal clarified that a publicly available product is part of the prior art as such, regardless of whether it can be reproduced. Its analysable properties are also included.
Consequences
- For applicants: anyone who sells their own product before filing endangers novelty – even if the formulation remains secret.
- For challengers: competitors’ marketed products can be used as prior art against patents, for example in oppositions or UPC revocation actions.
Case examples
Polymer patent attacked
A competitor had sold a polymer long before the priority date. We use the product as prior art in an opposition.
Filing before launch
A cosmetics manufacturer wanted to test-sell a new product before filing. In the light of G 1/23, we strongly advise filing first.
Frequently asked questions
Does the sale have to be proven?
Yes. Anyone relying on a marketed product must prove its availability and date, for example through invoices and catalogues.
Questions about your case? Our UPC team (Horak, Ziegeler, Karfusehr, Mai, Umberg, Gitmann-Kopilevich, Behrend, Friedlein) represents you before all divisions of the Unified Patent Court. Describe your case, contact form or call us: 0511 35 73 56-0.
This article reflects the legal position on its date of publication and does not replace legal advice in an individual case.
